Challenges and Impact of Formulation on Exposure to Drive PKPD in CNS Drug Discovery

10 September 2019 13:50 - 14:25

  • Early discovery compound characteristics often make high exposure for PKPD necessary and difficult to achieve
  • Driving CNS exposure is even more challenging due to the blood brain barrier
  • Dosing strategies to address this challenge are complicated and yield mixed results

Patrick Trapa, Principal Investigator, DMPK, Biogen